On September 4, GENSCRIPT BIO fell 5.34% in regular trading, trading at HK$34.5/share, with turnover of HK$276 million. The decline was triggered by the company's announcement of a proposed spin-off of its indirect non-wholly-owned subsidiary Probio Technology Limited for an independent listing on the Main Board of the Hong Kong Stock Exchange.

According to the announcement, Probio Technology operates the group's biologics and advanced therapy contract research, development, and manufacturing organization (CRDMO) services. The company had submitted an application to the HKEX under Practice Note 15 and received confirmation from the Listing Committee on August 14 to proceed with the proposed spin-off. Post-completion, GENSCRIPT BIO will retain a controlling interest in Probio, with its financial results continuing to be consolidated into the group's accounts.

The spin-off news came after a period of significant share price appreciation — the stock had rallied from a 52-week low of HK$10.36 to recent highs above HK$37 — likely prompting profit-taking. The company's H1 results showed revenue of approximately US$404.2 million, up 27.3% year-over-year, with adjusted net profit of US$62.5 million, up 203.3%, driven by surging AI-driven drug discovery demand and CRDMO recovery.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)